Loading…
BioAtla, Inc. is projected to rise to $4.24 by 2027, a +11% move from its current price of $3.82. BCAB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $3.63 | $3.82 | $4.03 | +0.01% |
| Jul 14 | $3.55 | $3.82 | $4.12 | +0.02% |
| Jul 15 | $3.49 | $3.82 | $4.18 | +0.03% |
| Jul 16 | $3.44 | $3.82 | $4.24 | +0.04% |
| Jul 17 | $3.40 | $3.82 | $4.30 | +0.05% |
| Jul 18 | $3.36 | $3.82 | $4.35 | +0.06% |
| Jul 19 | $3.33 | $3.82 | $4.39 | +0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.33 | $3.82 | $4.39 | +0.07% |
| Week 2 | $3.14 | $3.83 | $4.66 | +0.13% |
| Week 3 | $3.01 | $3.83 | $4.87 | +0.20% |
| Week 4 | $2.90 | $3.83 | $5.06 | +0.27% |
| Week 5 | $2.81 | $3.83 | $5.23 | +0.33% |
| Week 6 | $2.73 | $3.84 | $5.39 | +0.40% |
| Week 7 | $2.66 | $3.84 | $5.54 | +0.47% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma.
The company was founded in 2007 and is headquartered in San Diego, California.
BioAtla, Inc. (BCAB) is a healthcare stock currently trading at $3.59.
It holds a market capitalization of $5.96M and ranks 5267 by market cap.
The multi-year forecast outlines a path from a neutral near term toward bullish levels in the 2030s and beyond, with 2033–2050 showing rising averages and ROIs.
In particular, the forecast progresses from a 2026 average of $3.59 with a 0 ROI to stronger upside later, including 2033 average $4.65 with ROI 29.4, 2040 average $6.49 with ROI 80.8, and 2050 average $8.07 with ROI 124.8.
A major floor 31.1% below — a decisive break under it would weaken the trend.
The nearest floor, 13.4% below — buyers have tended to step in here.
The nearest ceiling, 19.9% above — a clean break opens room to run.
A major ceiling 147.4% above — clearing it would confirm fresh momentum.
Key BCAB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BCAB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.96 | Sell | $3.87 | Sell |
| MA 10 | $3.97 | Sell | $3.89 | Sell |
| MA 20 | $3.80 | Buy | $3.86 | Sell |
| MA 50 | $3.91 | Sell | $4.44 | Sell |
| MA 100 | $5.60 | Sell | $7.51 | Sell |
| MA 200 | $18.54 | Sell | $14.48 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.80 | Neutral |
| Stoch RSI (14) | 23.94 | Neutral |
| CCI (20) | 6.94 | Neutral |
| Williams %R (14) | -73.79 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 7.00 | Buy |
| Bollinger %B (20,2) | 0.52 | Neutral |
| Stochastic %K (14) | 26.21 | Neutral |
| TRIX (15) | -0.01 | Sell |
| Awesome (5,34) | 0.24 | Buy |
| Ultimate (7,14,28) | 45.49 | Neutral |
| Momentum (10) | 0.27 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 3.69 | Buy |
| ADX (14) | 13.33 | Neutral |
| ATR (14) | 0.21 | Info |
The near-term technical picture is NEUTRAL.
RSI14 is 40, suggesting modest downside pressure relative to overbought/oversold conditions.
The 50-day simple moving average (SMA50) is $3.93, while the 200-day simple moving average (SMA200) is $18.81.
Nearby support is pegged at $3.31 and resistance at $4.58, with the 30-day price range spanning from $2.50 to $5.15.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.31 | $3.82 | $5.51 | 0% | Neutral | |
| $3.09 | $4.24 | $6.30 | +11% | Neutral | |
| $2.50 | $3.65 | $5.77 | -4% | Neutral | |
| $2.25 | $3.45 | $5.73 | -10% | Neutral | |
| $2.14 | $3.44 | $5.94 | -10% | Neutral | |
| $2.00 | $3.35 | $5.98 | -12% | Neutral | |
| $2.59 | $4.53 | $8.34 | +19% | Neutral | |
| $2.72 | $4.94 | $9.34 | +29% | Bullish | |
| $2.58 | $4.88 | $9.47 | +28% | Bullish | |
| $2.68 | $5.26 | $10.43 | +38% | Bullish | |
| $3.09 | $6.87 | $14.97 | +80% | Bullish | |
| $3.92 | $8.71 | $20.02 | +128% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.31 | $3.82 | $4.67 | +0.00% |
| August 2026 | $3.26 | $3.95 | $4.98 | +3.41% |
| September 2026 | $3.14 | $3.85 | $4.96 | -2.45% |
| October 2026 | $2.98 | $3.71 | $4.85 | -3.79% |
| November 2026 | $3.11 | $3.90 | $5.18 | +5.29% |
| December 2026 | $3.24 | $4.10 | $5.51 | +5.05% |
Click any year to see its month-by-month BCAB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BCAB is projected to trade between $3.31 and $5.51, averaging $3.82 — a potential gain of 0% from today's $3.82. A consolidation phase looks the most probable path here.
BioAtla, Inc.'s 2027 outlook centres on $4.24, within a $3.09 to $6.30 range. That is up +11% on the projected 2026 average. That marks a +11% change versus current levels. Price action looks broadly range-bound.
By 2028, BCAB could reach as high as $5.77, with a base case around $3.65 and support toward $2.50 — roughly -4% from $3.82. A consolidation phase looks the most probable path here.
Expect BCAB to range from $2.25 to $5.73 through 2029. The $3.45 average target implies a -10% move from current prices. That is -5% versus the projected 2028 average. Price action looks broadly range-bound.
The BCAB price prediction for 2030 points to an average of $3.44 (low $2.14, high $5.94) — a potential decline of -10% on today's $3.82. A consolidation phase looks the most probable path here.
In 2031, BCAB is projected to trade between $2.00 and $5.98, averaging $3.35 — a potential decline of -12% from today's $3.82. That is -3% versus the projected 2030 average. Price action looks broadly range-bound.
BioAtla, Inc.'s 2032 outlook centres on $4.53, within a $2.59 to $8.34 range. That is up +35% on the projected 2031 average. That marks a +19% change versus current levels. A consolidation phase looks the most probable path here.
By 2033, BCAB could reach as high as $9.34, with a base case around $4.94 and support toward $2.72 — roughly +29% from $3.82. Momentum favours further upside here.
Expect BCAB to range from $2.58 to $9.47 through 2034. The $4.88 average target implies a +28% move from current prices. That is -1% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The BCAB price prediction for 2035 points to an average of $5.26 (low $2.68, high $10.43) — a potential gain of +38% on today's $3.82. Momentum favours further upside here.
In 2040, BCAB is projected to trade between $3.09 and $14.97, averaging $6.87 — a potential gain of +80% from today's $3.82. That is up +31% on the projected 2035 average. Buyers look set to stay in control over this stretch.
BioAtla, Inc.'s 2050 outlook centres on $8.71, within a $3.92 to $20.02 range. That is up +27% on the projected 2040 average. That marks a +128% change versus current levels. Momentum favours further upside here.
Investing $1,000 in BCAB today (≈ 261.780105 BCAB) could be worth
$2,278.92
+$1,278.92 (+128%) by 2050 · US Dollar
Based on the average projected BCAB price of $8.71 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BCABwould be worth at today's price.
$1,000 invested in BCAB on Jul 10, 2025 (≈ 51.679586 BCAB) would be worth
$197.42
-$802.58 (-80.3%) today · 0.20× · US Dollar
Based on a BCAB entry price of $19.35 vs. today's $3.82.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.19 | $911.69 | -8.8% |
| 1 month ago | $3.65 | $1,046.58 | +4.7% |
| 3 months ago | $4.46 | $856.5 | -14.3% |
| 6 months ago | $15.75 | $242.54 | -75.7% |
| 1 year ago | $19.35 | $197.42 | -80.3% |
| All time (5.0y) ago | $1,978.5 | $1.93 | -99.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BCAB forecast.
Our base-case forecast reaches $7.60 around 2050.
Implied market cap at $7.60: $12.61M
The multi-year forecast shows a mixed but progressively favorable path after a neutral start.
The 2026 forecast lists a min of $3.31, an avg of $3.59, and a max of $5.21, with an ROI of 0 and a NEUTRAL sentiment.
Looking ahead, 2033-2035 shift to BULLISH, with 2033 avg $4.65 and ROI 29.4, 2034 avg $4.61 and ROI 28.4, and 2035 avg $4.93 and ROI 37.4.
The longer horizon shows strong upside: 2040 avg $6.49 and ROI 80.8, and 2050 avg $8.07 and ROI 124.8, indicating meaningful longer-term appreciation potential.
However, earlier years exhibit negative or flat performance, such as 2027 ROI 11, 2028 ROI -4.4, 2029 ROI -10.5, 2030 ROI -11, and 2031 ROI -12.9, underscoring uncertainty and downside risk. These are estimates, not guarantees, and actual results may differ.
Tap a question to reveal the answer.
The forecast for 2030 shows an avg price of $3.20, with a min of $1.98, a max of $5.55, and an ROI of -11; sentiment NEUTRAL.
Near-term signals are NEUTRAL with a 0 ROI in 2026 and a positive ROI in 2027 (11). The forecast turns bullish in 2033 onward, with 2033 ROI 29.4 and 2040 ROI 80.8, culminating in 2050 ROI 124.8. These are estimates and not guarantees.
Based on the forecast, the maximum in the horizon is $18.57 in 2050, so reaching higher levels like $10 is within the modeled range, though not guaranteed.
2033 average price is $4.65, with a min of $2.53 and a max of $8.85; ROI 29.4; sentiment BULLISH.
The 30-day range is from $2.50 to $5.15.
BioAtla, Inc. Community Discussion
0Share your BioAtla, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.